增强CT影像特征联合临床因素预测肝癌TACE疗效与预后
该回顾性研究纳入399例中晚期肝细胞癌患者,基于动脉期增强CT建立深度学习-影像组学-临床因素联合模型(DLRC),用于预测TACE治疗反应。DLRC模型在训练集和验证集的AUC分别为0.937和0.909,优于单一或双特征模型,且模型输出是全因生存的独立危险因素。
要点
- DLRC模型基于动脉期增强CT的19个定量影像组学特征、10个深度学习特征及3个临床因素构建。
- DLRC预测TACE治疗反应的AUC在训练集为0.937、验证集为0.909,净临床获益优于单一模型。
- DLRC输出是全因生存的独立危险因素(HR 1.20,95%CI 1.03-1.40,P=0.019)。
核心结论
- DLRC模型预测中晚期HCC患者TACE治疗反应准确性较高,可作为精准治疗的有力工具。
研究设计与样本
- 回顾性研究,纳入399例中晚期肝细胞癌患者,基于动脉期增强CT图像建立深度学习与影像组学特征。
- 采用相关分析和LASSO回归进行特征筛选,通过多变量逻辑回归构建DLRC联合模型。
- 用AUC、校准曲线和决策曲线分析(DCA)评估模型性能,并用Kaplan-Meier生存曲线在随访队列(n=261)中评估总生存。
诊断标准与关键数值
- DLRC模型由19个定量影像组学特征、10个深度学习特征和3个临床因素构成。
- DLRC模型预测TACE治疗反应的AUC在训练集为0.937(95%CI 0.912-0.962),在验证集为0.909(95%CI 0.850-0.968)。
- DLRC模型性能优于两个特征签名或单一特征签名建立的模型(p<0.05)。
- 多变量Cox回归显示DLRC模型输出是总生存的独立危险因素(HR 1.20,95%CI 1.03-1.40,p=0.019)。
临床应用与阅片要点
- 可基于动脉期增强CT提取的影像组学和深度学习特征联合临床因素,辅助预测中晚期HCC患者TACE治疗反应。
- DLRC模型输出可作为总生存的独立预后因素,提示高风险患者可能需更密切随访或联合治疗。
局限性
- 本研究为回顾性设计,可能存在选择偏倚。
- 原文未报告外部多中心验证,模型泛化能力需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Accurate prediction of treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) is critical for precision treatment. This study aimed to develop a comprehensive model (DLRC) that incorporates contrast-enhanced computed tomography (CECT) images and clinical factors to predict the response to TACE in patients with HCC.
MATERIALS AND METHODS: A total of 399 patients with intermediate-stage HCC were included in this retrospective study. Deep learning and radiomic signatures were established based on arterial phase CECT images, Correlation analysis and the least absolute shrinkage and selection (LASSO) regression analysis were applied for features selection. The DLRC model incorporating deep learning radiomic signatures and clinical factors was developed using multivariate logistic regression. The area under the receiver operating characteristic curve (AUC), calibration curve and decision curve analysis (DCA) were used to evaluate the performance of the models. Kaplan-Meier survival curves based on the DLRC were plotted to assess overall survival in the follow-up cohort (n = 261).
RESULTS: The DLRC model was developed using 19 quantitative radiomic features, 10 deep learning features, and 3 clinical factors. The AUC of the DLRC model was 0.937 (95% confidence interval [CI], 0.912-0.962) and 0.909 (95% CI, 0.850-0.968) in the training and validation cohorts, respectively, outperforming models established with two signatures or a single signature (p < 0.05). Stratified analysis showed that the DLRC was not statistically different between subgroups (p > 0.05), and the DCA confirmed the greater net clinical benefit. In addition, multivariable cox regression revealed that DLRC model outputs were independent risk factors for the overall survival (hazard ratios: 1.20, 95% CI: 1.03-1.40; p = 0.019).
CONCLUSION: The DLRC model exhibited a remarkable accuracy in predicting response to TACE, and it can be utilized as a potent tool for precision treatment.
引用
- Sun, Shi, Xin, et al. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. Acad Radiol. 2023. PMID: 36803649. doi:10.1016/j.acra.2022.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。